Literature DB >> 35581545

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.

Stephanie J Nahas1, Steffen Naegel2, Joshua M Cohen3, Xiaoping Ning3, Lindsay Janka3, Verena Ramirez Campos3, Lynda J Krasenbaum3, Dagny Holle-Lee4, David Kudrow5, Christian Lampl6,7.   

Abstract

Entities:  

Year:  2022        PMID: 35581545      PMCID: PMC9112594          DOI: 10.1186/s10194-022-01423-x

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.
Correction to: J Headache Pain 22, 141 (2021) https://doi.org/10.1186/s10194-021-01351-2 Following the publication of the original article [1], we were notified that the x-axis labels for part B of Figure 1 were incorrect in the previous version and had accidentally been duplicated from part A. Originally published Figure 1: Corrected Figures: The original article has been corrected.
  1 in total

1.  Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.

Authors:  Stephanie J Nahas; Steffen Naegel; Joshua M Cohen; Xiaoping Ning; Lindsay Janka; Verena Ramirez Campos; Lynda J Krasenbaum; Dagny Holle-Lee; David Kudrow; Christian Lampl
Journal:  J Headache Pain       Date:  2021-11-24       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.